nodes	percent_of_prediction	percent_of_DWPC	metapath
Bisacodyl—GPR55—pancreas—stomach cancer	0.113	0.456	CbGeAlD
Bisacodyl—GPR55—endocrine gland—stomach cancer	0.08	0.322	CbGeAlD
Bisacodyl—GPR55—lymph node—stomach cancer	0.0553	0.222	CbGeAlD
Bisacodyl—Blood in stool—Capecitabine—stomach cancer	0.0285	0.074	CcSEcCtD
Bisacodyl—GPR55—GPCRs, Other—HRH4—stomach cancer	0.0279	0.0761	CbGpPWpGaD
Bisacodyl—GPR55—GPCRs, Other—F2R—stomach cancer	0.0161	0.0437	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—KISS1R—stomach cancer	0.0144	0.0392	CbGpPWpGaD
Bisacodyl—Cramp muscle—Floxuridine—stomach cancer	0.0134	0.0348	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—HRH4—stomach cancer	0.0131	0.0356	CbGpPWpGaD
Bisacodyl—GPR55—GPCRs, Other—ADRB2—stomach cancer	0.0118	0.0323	CbGpPWpGaD
Bisacodyl—Haematochezia—Capecitabine—stomach cancer	0.0116	0.0302	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—KISS1R—stomach cancer	0.011	0.0299	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—HRH4—stomach cancer	0.0104	0.0283	CbGpPWpGaD
Bisacodyl—Abdominal cramps—Irinotecan—stomach cancer	0.0103	0.0269	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—KISS1—stomach cancer	0.00927	0.0253	CbGpPWpGaD
Bisacodyl—Muscle spasms—Floxuridine—stomach cancer	0.00861	0.0224	CcSEcCtD
Bisacodyl—Haematochezia—Epirubicin—stomach cancer	0.00808	0.021	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—HRH4—stomach cancer	0.00792	0.0216	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—AGTR2—stomach cancer	0.0076	0.0207	CbGpPWpGaD
Bisacodyl—Haematochezia—Doxorubicin—stomach cancer	0.00747	0.0195	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—HTR1A—stomach cancer	0.00731	0.0199	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Floxuridine—stomach cancer	0.00731	0.019	CcSEcCtD
Bisacodyl—Nervous system disorder—Floxuridine—stomach cancer	0.00716	0.0186	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—ANXA1—stomach cancer	0.00706	0.0192	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—KISS1—stomach cancer	0.00706	0.0192	CbGpPWpGaD
Bisacodyl—Colitis—Irinotecan—stomach cancer	0.0067	0.0174	CcSEcCtD
Bisacodyl—Syncope—Mitomycin—stomach cancer	0.0063	0.0164	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—KISS1R—stomach cancer	0.00619	0.0169	CbGpPWpGaD
Bisacodyl—Loss of consciousness—Mitomycin—stomach cancer	0.00617	0.0161	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—AGTR2—stomach cancer	0.00604	0.0165	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—F2R—stomach cancer	0.00597	0.0163	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Floxuridine—stomach cancer	0.00597	0.0155	CcSEcCtD
Bisacodyl—Anorectal discomfort—Epirubicin—stomach cancer	0.00595	0.0155	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—HTR1A—stomach cancer	0.00582	0.0158	CbGpPWpGaD
Bisacodyl—Abdominal pain—Floxuridine—stomach cancer	0.00578	0.015	CcSEcCtD
Bisacodyl—Shock—Mitomycin—stomach cancer	0.00564	0.0147	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—KISS1R—stomach cancer	0.00562	0.0153	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—ANXA1—stomach cancer	0.00562	0.0153	CbGpPWpGaD
Bisacodyl—Anorectal discomfort—Doxorubicin—stomach cancer	0.00551	0.0143	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—ADRB1—stomach cancer	0.00544	0.0148	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Floxuridine—stomach cancer	0.00538	0.014	CcSEcCtD
Bisacodyl—Diarrhoea—Floxuridine—stomach cancer	0.005	0.013	CcSEcCtD
Bisacodyl—Dehydration—Irinotecan—stomach cancer	0.00471	0.0123	CcSEcCtD
Bisacodyl—Vomiting—Floxuridine—stomach cancer	0.00465	0.0121	CcSEcCtD
Bisacodyl—Colitis—Docetaxel—stomach cancer	0.00463	0.0121	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—AGTR2—stomach cancer	0.0046	0.0125	CbGpPWpGaD
Bisacodyl—Headache—Floxuridine—stomach cancer	0.00458	0.0119	CcSEcCtD
Bisacodyl—Cramp muscle—Irinotecan—stomach cancer	0.00456	0.0119	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—F2R—stomach cancer	0.00455	0.0124	CbGpPWpGaD
Bisacodyl—Colitis—Capecitabine—stomach cancer	0.00448	0.0117	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—HRH4—stomach cancer	0.00448	0.0122	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—HTR1A—stomach cancer	0.00443	0.0121	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—ADRB2—stomach cancer	0.00441	0.012	CbGpPWpGaD
Bisacodyl—Nausea—Floxuridine—stomach cancer	0.00434	0.0113	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—ANXA1—stomach cancer	0.00428	0.0117	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—ADRB1—stomach cancer	0.00414	0.0113	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—HRH4—stomach cancer	0.00406	0.0111	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—KISS1—stomach cancer	0.00399	0.0109	CbGpPWpGaD
Bisacodyl—Diarrhoea—Mitomycin—stomach cancer	0.00392	0.0102	CcSEcCtD
Bisacodyl—Dizziness—Mitomycin—stomach cancer	0.00379	0.00987	CcSEcCtD
Bisacodyl—Vomiting—Mitomycin—stomach cancer	0.00365	0.00949	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—KISS1—stomach cancer	0.00362	0.00987	CbGpPWpGaD
Bisacodyl—Headache—Mitomycin—stomach cancer	0.00359	0.00935	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—RGS2—stomach cancer	0.00343	0.00935	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—GAST—stomach cancer	0.00343	0.00935	CbGpPWpGaD
Bisacodyl—Nausea—Mitomycin—stomach cancer	0.00341	0.00886	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—ADRB2—stomach cancer	0.00336	0.00915	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GLI3—stomach cancer	0.00332	0.00905	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—KISS1R—stomach cancer	0.00332	0.00905	CbGpPWpGaD
Bisacodyl—Dehydration—Docetaxel—stomach cancer	0.00326	0.00847	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—RBP1—stomach cancer	0.00317	0.00863	CbGpPWpGaD
Bisacodyl—Immune system disorder—Irinotecan—stomach cancer	0.00317	0.00824	CcSEcCtD
Bisacodyl—Cramp muscle—Docetaxel—stomach cancer	0.00315	0.00821	CcSEcCtD
Bisacodyl—Dehydration—Capecitabine—stomach cancer	0.00315	0.0082	CcSEcCtD
Bisacodyl—Colitis—Epirubicin—stomach cancer	0.00312	0.00813	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—GAST—stomach cancer	0.00312	0.00849	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—RGS2—stomach cancer	0.00312	0.00849	CbGpPWpGaD
Bisacodyl—Muscle spasms—Irinotecan—stomach cancer	0.00293	0.00763	CcSEcCtD
Bisacodyl—Colitis—Doxorubicin—stomach cancer	0.00289	0.00752	CcSEcCtD
Bisacodyl—Abdominal discomfort—Capecitabine—stomach cancer	0.00281	0.00731	CcSEcCtD
Bisacodyl—Syncope—Irinotecan—stomach cancer	0.00274	0.00712	CcSEcCtD
Bisacodyl—Loss of consciousness—Irinotecan—stomach cancer	0.00268	0.00698	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—CXCL8—stomach cancer	0.00268	0.00729	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—AGTR2—stomach cancer	0.0026	0.00708	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—WWOX—stomach cancer	0.00258	0.00704	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—F2R—stomach cancer	0.00257	0.007	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—HTR1A—stomach cancer	0.0025	0.00682	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Irinotecan—stomach cancer	0.00249	0.00648	CcSEcCtD
Bisacodyl—Shock—Irinotecan—stomach cancer	0.00245	0.00637	CcSEcCtD
Bisacodyl—Nervous system disorder—Irinotecan—stomach cancer	0.00244	0.00635	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—ANXA1—stomach cancer	0.00242	0.00659	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—HRH4—stomach cancer	0.0024	0.00654	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—WIF1—stomach cancer	0.0024	0.00654	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Fluorouracil—stomach cancer	0.00238	0.00621	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—AGTR2—stomach cancer	0.00236	0.00643	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—ADRB1—stomach cancer	0.00234	0.00638	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Fluorouracil—stomach cancer	0.00234	0.00609	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—F2R—stomach cancer	0.00233	0.00636	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—HTR1A—stomach cancer	0.00227	0.00619	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PRKAB1—stomach cancer	0.00222	0.00604	CbGpPWpGaD
Bisacodyl—Dehydration—Epirubicin—stomach cancer	0.0022	0.00572	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—ANXA1—stomach cancer	0.0022	0.00598	CbGpPWpGaD
Bisacodyl—Immune system disorder—Docetaxel—stomach cancer	0.00219	0.00569	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Irinotecan—stomach cancer	0.00215	0.00559	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—RNF43—stomach cancer	0.00214	0.00583	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—KISS1—stomach cancer	0.00214	0.00583	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CXCL8—stomach cancer	0.00213	0.0058	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—ADRB1—stomach cancer	0.00213	0.00579	CbGpPWpGaD
Bisacodyl—Immune system disorder—Capecitabine—stomach cancer	0.00212	0.00551	CcSEcCtD
Bisacodyl—Malnutrition—Docetaxel—stomach cancer	0.00211	0.00549	CcSEcCtD
Bisacodyl—Abdominal discomfort—Methotrexate—stomach cancer	0.00209	0.00544	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Fluorouracil—stomach cancer	0.00206	0.00536	CcSEcCtD
Bisacodyl—Malnutrition—Capecitabine—stomach cancer	0.00204	0.00531	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Irinotecan—stomach cancer	0.00204	0.0053	CcSEcCtD
Bisacodyl—Dehydration—Doxorubicin—stomach cancer	0.00203	0.00529	CcSEcCtD
Bisacodyl—Muscle spasms—Docetaxel—stomach cancer	0.00203	0.00528	CcSEcCtD
Bisacodyl—Abdominal pain—Irinotecan—stomach cancer	0.00197	0.00512	CcSEcCtD
Bisacodyl—Muscle spasms—Capecitabine—stomach cancer	0.00196	0.00511	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—FST—stomach cancer	0.00191	0.0052	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—ADRB2—stomach cancer	0.0019	0.00517	CbGpPWpGaD
Bisacodyl—Syncope—Docetaxel—stomach cancer	0.00189	0.00492	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—HBEGF—stomach cancer	0.00187	0.00509	CbGpPWpGaD
Bisacodyl—Loss of consciousness—Docetaxel—stomach cancer	0.00185	0.00482	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—RGS2—stomach cancer	0.00184	0.00501	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GAST—stomach cancer	0.00184	0.00501	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Irinotecan—stomach cancer	0.00183	0.00477	CcSEcCtD
Bisacodyl—Syncope—Capecitabine—stomach cancer	0.00183	0.00476	CcSEcCtD
Bisacodyl—Loss of consciousness—Capecitabine—stomach cancer	0.00179	0.00467	CcSEcCtD
Bisacodyl—Hypersensitivity—Fluorouracil—stomach cancer	0.00176	0.00457	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—FGG—stomach cancer	0.00174	0.00475	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—ADRB2—stomach cancer	0.00172	0.00469	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Docetaxel—stomach cancer	0.00172	0.00448	CcSEcCtD
Bisacodyl—Diarrhoea—Irinotecan—stomach cancer	0.0017	0.00443	CcSEcCtD
Bisacodyl—Shock—Docetaxel—stomach cancer	0.00169	0.00441	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—PPP2R1A—stomach cancer	0.00169	0.0046	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Docetaxel—stomach cancer	0.00169	0.00439	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PRKAA1—stomach cancer	0.00168	0.00458	CbGpPWpGaD
Bisacodyl—Dizziness—Irinotecan—stomach cancer	0.00165	0.00428	CcSEcCtD
Bisacodyl—Shock—Capecitabine—stomach cancer	0.00164	0.00427	CcSEcCtD
Bisacodyl—Nervous system disorder—Capecitabine—stomach cancer	0.00163	0.00425	CcSEcCtD
Bisacodyl—Diarrhoea—Fluorouracil—stomach cancer	0.00163	0.00425	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—RBP4—stomach cancer	0.00162	0.00442	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CXCL8—stomach cancer	0.00162	0.00442	CbGpPWpGaD
Bisacodyl—Vomiting—Irinotecan—stomach cancer	0.00158	0.00412	CcSEcCtD
Bisacodyl—Immune system disorder—Methotrexate—stomach cancer	0.00158	0.0041	CcSEcCtD
Bisacodyl—Dizziness—Fluorouracil—stomach cancer	0.00158	0.0041	CcSEcCtD
Bisacodyl—Headache—Irinotecan—stomach cancer	0.00156	0.00406	CcSEcCtD
Bisacodyl—Malnutrition—Methotrexate—stomach cancer	0.00152	0.00396	CcSEcCtD
Bisacodyl—Vomiting—Fluorouracil—stomach cancer	0.00152	0.00395	CcSEcCtD
Bisacodyl—Headache—Fluorouracil—stomach cancer	0.00149	0.00389	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Docetaxel—stomach cancer	0.00149	0.00387	CcSEcCtD
Bisacodyl—Nausea—Irinotecan—stomach cancer	0.00148	0.00385	CcSEcCtD
Bisacodyl—Immune system disorder—Epirubicin—stomach cancer	0.00148	0.00384	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Capecitabine—stomach cancer	0.00144	0.00374	CcSEcCtD
Bisacodyl—Malnutrition—Epirubicin—stomach cancer	0.00142	0.0037	CcSEcCtD
Bisacodyl—Nausea—Fluorouracil—stomach cancer	0.00142	0.00369	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Docetaxel—stomach cancer	0.00141	0.00366	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—HSPB1—stomach cancer	0.00139	0.0038	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—AGTR2—stomach cancer	0.00139	0.0038	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—BMP2—stomach cancer	0.00138	0.00376	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—F2R—stomach cancer	0.00138	0.00376	CbGpPWpGaD
Bisacodyl—Muscle spasms—Epirubicin—stomach cancer	0.00137	0.00356	CcSEcCtD
Bisacodyl—Immune system disorder—Doxorubicin—stomach cancer	0.00137	0.00355	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Capecitabine—stomach cancer	0.00136	0.00355	CcSEcCtD
Bisacodyl—Abdominal pain—Docetaxel—stomach cancer	0.00136	0.00354	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—AKR1C3—stomach cancer	0.00136	0.0037	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—HTR1A—stomach cancer	0.00134	0.00366	CbGpPWpGaD
Bisacodyl—Abdominal pain—Capecitabine—stomach cancer	0.00132	0.00343	CcSEcCtD
Bisacodyl—Malnutrition—Doxorubicin—stomach cancer	0.00132	0.00342	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—PRKCB—stomach cancer	0.0013	0.00354	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—ANXA1—stomach cancer	0.0013	0.00353	CbGpPWpGaD
Bisacodyl—Syncope—Epirubicin—stomach cancer	0.00128	0.00332	CcSEcCtD
Bisacodyl—Hypersensitivity—Docetaxel—stomach cancer	0.00127	0.0033	CcSEcCtD
Bisacodyl—Muscle spasms—Doxorubicin—stomach cancer	0.00127	0.00329	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—ADRB1—stomach cancer	0.00126	0.00342	CbGpPWpGaD
Bisacodyl—Loss of consciousness—Epirubicin—stomach cancer	0.00125	0.00325	CcSEcCtD
Bisacodyl—Anaphylactic shock—Methotrexate—stomach cancer	0.00124	0.00323	CcSEcCtD
Bisacodyl—Hypersensitivity—Capecitabine—stomach cancer	0.00123	0.00319	CcSEcCtD
Bisacodyl—Nervous system disorder—Methotrexate—stomach cancer	0.00122	0.00317	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—RPS6—stomach cancer	0.0012	0.00327	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PRKCB—stomach cancer	0.00118	0.00322	CbGpPWpGaD
Bisacodyl—Syncope—Doxorubicin—stomach cancer	0.00118	0.00307	CcSEcCtD
Bisacodyl—Diarrhoea—Docetaxel—stomach cancer	0.00118	0.00306	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—IL6ST—stomach cancer	0.00118	0.0032	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Epirubicin—stomach cancer	0.00116	0.00302	CcSEcCtD
Bisacodyl—Loss of consciousness—Doxorubicin—stomach cancer	0.00116	0.00301	CcSEcCtD
Bisacodyl—Shock—Epirubicin—stomach cancer	0.00114	0.00297	CcSEcCtD
Bisacodyl—Diarrhoea—Capecitabine—stomach cancer	0.00114	0.00297	CcSEcCtD
Bisacodyl—Nervous system disorder—Epirubicin—stomach cancer	0.00114	0.00296	CcSEcCtD
Bisacodyl—Dizziness—Docetaxel—stomach cancer	0.00114	0.00296	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—HBEGF—stomach cancer	0.0011	0.003	CbGpPWpGaD
Bisacodyl—Dizziness—Capecitabine—stomach cancer	0.0011	0.00287	CcSEcCtD
Bisacodyl—Vomiting—Docetaxel—stomach cancer	0.00109	0.00285	CcSEcCtD
Bisacodyl—Headache—Docetaxel—stomach cancer	0.00108	0.00281	CcSEcCtD
Bisacodyl—Anaphylactic shock—Doxorubicin—stomach cancer	0.00107	0.0028	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Methotrexate—stomach cancer	0.00107	0.00279	CcSEcCtD
Bisacodyl—Vomiting—Capecitabine—stomach cancer	0.00106	0.00276	CcSEcCtD
Bisacodyl—Shock—Doxorubicin—stomach cancer	0.00106	0.00275	CcSEcCtD
Bisacodyl—Nervous system disorder—Doxorubicin—stomach cancer	0.00105	0.00274	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—IL6R—stomach cancer	0.00105	0.00286	CbGpPWpGaD
Bisacodyl—Headache—Capecitabine—stomach cancer	0.00104	0.00272	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—RHOA—stomach cancer	0.00104	0.00284	CbGpPWpGaD
Bisacodyl—Nausea—Docetaxel—stomach cancer	0.00102	0.00266	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—ADRB2—stomach cancer	0.00102	0.00277	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Methotrexate—stomach cancer	0.00101	0.00264	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Epirubicin—stomach cancer	0.001	0.00261	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PPP2R1A—stomach cancer	0.000997	0.00272	CbGpPWpGaD
Bisacodyl—Nausea—Capecitabine—stomach cancer	0.00099	0.00258	CcSEcCtD
Bisacodyl—Abdominal pain—Methotrexate—stomach cancer	0.000981	0.00255	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Epirubicin—stomach cancer	0.000949	0.00247	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—RHOA—stomach cancer	0.000948	0.00258	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.000927	0.00241	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—SMAD4—stomach cancer	0.000926	0.00252	CbGpPWpGaD
Bisacodyl—Abdominal pain—Epirubicin—stomach cancer	0.000918	0.00239	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CXCL8—stomach cancer	0.000916	0.0025	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Methotrexate—stomach cancer	0.000914	0.00238	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—FYN—stomach cancer	0.000879	0.0024	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Doxorubicin—stomach cancer	0.000878	0.00229	CcSEcCtD
Bisacodyl—Hypersensitivity—Epirubicin—stomach cancer	0.000855	0.00223	CcSEcCtD
Bisacodyl—Abdominal pain—Doxorubicin—stomach cancer	0.000849	0.00221	CcSEcCtD
Bisacodyl—Diarrhoea—Methotrexate—stomach cancer	0.000849	0.00221	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—CXCL8—stomach cancer	0.000832	0.00227	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—FGFR2—stomach cancer	0.000825	0.00225	CbGpPWpGaD
Bisacodyl—Dizziness—Methotrexate—stomach cancer	0.00082	0.00213	CcSEcCtD
Bisacodyl—Diarrhoea—Epirubicin—stomach cancer	0.000794	0.00207	CcSEcCtD
Bisacodyl—Hypersensitivity—Doxorubicin—stomach cancer	0.000791	0.00206	CcSEcCtD
Bisacodyl—Vomiting—Methotrexate—stomach cancer	0.000789	0.00205	CcSEcCtD
Bisacodyl—Headache—Methotrexate—stomach cancer	0.000777	0.00202	CcSEcCtD
Bisacodyl—Dizziness—Epirubicin—stomach cancer	0.000768	0.002	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—IRS2—stomach cancer	0.000756	0.00206	CbGpPWpGaD
Bisacodyl—Vomiting—Epirubicin—stomach cancer	0.000738	0.00192	CcSEcCtD
Bisacodyl—Nausea—Methotrexate—stomach cancer	0.000737	0.00192	CcSEcCtD
Bisacodyl—Diarrhoea—Doxorubicin—stomach cancer	0.000735	0.00191	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CAV1—stomach cancer	0.000733	0.002	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—APOA1—stomach cancer	0.000731	0.00199	CbGpPWpGaD
Bisacodyl—Headache—Epirubicin—stomach cancer	0.000727	0.00189	CcSEcCtD
Bisacodyl—Dizziness—Doxorubicin—stomach cancer	0.00071	0.00185	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PRKCB—stomach cancer	0.000697	0.0019	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IL6ST—stomach cancer	0.000695	0.00189	CbGpPWpGaD
Bisacodyl—Nausea—Epirubicin—stomach cancer	0.00069	0.00179	CcSEcCtD
Bisacodyl—Vomiting—Doxorubicin—stomach cancer	0.000683	0.00178	CcSEcCtD
Bisacodyl—Headache—Doxorubicin—stomach cancer	0.000673	0.00175	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—APC—stomach cancer	0.000667	0.00182	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—MAPK3—stomach cancer	0.000639	0.00174	CbGpPWpGaD
Bisacodyl—Nausea—Doxorubicin—stomach cancer	0.000638	0.00166	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—IL6R—stomach cancer	0.00062	0.00169	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—MAPK1—stomach cancer	0.000608	0.00166	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—EGFR—stomach cancer	0.000608	0.00166	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3CA—stomach cancer	0.000581	0.00158	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SERPINE1—stomach cancer	0.00058	0.00158	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—KRAS—stomach cancer	0.000574	0.00157	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—RHOA—stomach cancer	0.00056	0.00153	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NOS3—stomach cancer	0.000554	0.00151	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PIK3CA—stomach cancer	0.000528	0.00144	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—ERBB2—stomach cancer	0.000518	0.00141	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CXCL8—stomach cancer	0.000491	0.00134	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—HRAS—stomach cancer	0.000488	0.00133	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CDKN1B—stomach cancer	0.00048	0.00131	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—IL6—stomach cancer	0.000467	0.00127	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CCND1—stomach cancer	0.000458	0.00125	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—JUN—stomach cancer	0.000457	0.00124	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MMP9—stomach cancer	0.000444	0.00121	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CDKN1A—stomach cancer	0.000443	0.00121	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MAPK8—stomach cancer	0.000432	0.00118	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—VEGFA—stomach cancer	0.000399	0.00109	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—STAT3—stomach cancer	0.000395	0.00108	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MAPK3—stomach cancer	0.000378	0.00103	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MYC—stomach cancer	0.000367	0.001	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MAPK1—stomach cancer	0.000359	0.000979	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—EGFR—stomach cancer	0.000359	0.000979	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—KRAS—stomach cancer	0.000339	0.000925	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PIK3CA—stomach cancer	0.000312	0.000849	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TP53—stomach cancer	0.000302	0.000822	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—HRAS—stomach cancer	0.000288	0.000786	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IL6—stomach cancer	0.000276	0.000752	CbGpPWpGaD
